Tango Therapeutics, Inc. (TNGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on June 5, 2024, specifically the Company's 2024 Annual Meeting of Stockholders. The meeting was held in a virtual-only format. As of the record date (April 9, 2024), there were 106,735,395 shares of Common Stock outstanding. A quorum was established with 100,708,013 shares present or represented (94.35% of entitled shares).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance actions and voting results rather than financial performance data.
Material Changes and Voting Results
Stockholders approved three key proposals at the Annual Meeting:
- Proposal 1 (Election of Directors): Three Class III director nominees were elected to serve until the 2027 annual meeting:
- Alexis Borisy: 91,323,366 For; 4,133,485 Withheld.
- John Ketchum: 95,418,237 For; 38,614 Withheld.
- Barbara Weber, M.D.: 93,016,008 For; 2,440,843 Withheld.
- Proposal 2 (Auditor Ratification): The selection of PricewaterhouseCoopers, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified with 100,705,526 votes For and 2,363 Against.
- Proposal 3 (Charter Amendment): Stockholders approved an amendment to the Second Amended and Restated Certificate of Incorporation to limit the liability of certain officers, permitted by recent Delaware law amendments. The Certificate of Amendment was filed with the Delaware Secretary of State on June 5, 2024, and became effective immediately. Results: 89,901,508 For; 5,553,824 Against.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, or contingencies beyond the standard incorporation of the Certificate of Amendment by reference.
Key Facts for Investor Verification
- Verify the specific language of the officer liability limitation in the attached Certificate of Amendment (Exhibit 3.1).
- Confirm the tenure of the newly elected Class III directors (Alexis Borisy, John Ketchum, Barbara Weber) extends through the 2027 annual meeting.
- Note that PricewaterhouseCoopers, LLP has been ratified as the auditor for the fiscal year ending December 31, 2024.
- Review the full Proxy Statement filed on April 29, 2024, for detailed background on the proposals and director biographies.